Creating a vaccine using B cells to treat brain cancer.
Development of a B Cell Based Vaccine for the Treatment of Newly Diagnosed Malignant Gliomas
This study is testing a new vaccine designed to help people with newly diagnosed brain cancer by boosting their immune system to fight the tumors better, and it will be personalized for each patient.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10898601 on NIH RePORTER |
What this research studies
This research focuses on developing a B-cell-based vaccine (BVax) aimed at treating newly diagnosed malignant gliomas, a type of brain cancer. The vaccine is designed to enhance the immune response against tumors by activating B cells and promoting the survival of CD8+ T cells, which are crucial for attacking cancer cells. The approach includes preclinical studies that have shown promising results in animal models, and the research aims to translate these findings into a clinical trial for human patients. The project will involve manufacturing personalized BVax and CD8 T cells for each patient and assessing their immune response to the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been newly diagnosed with malignant gliomas.
Not a fit: Patients with advanced or recurrent gliomas, or those who do not meet the eligibility criteria for the clinical trial, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new and effective treatment option for patients with malignant gliomas, potentially improving their survival and quality of life.
How similar studies have performed: Other research has shown success with immunotherapy approaches in cancer treatment, but this specific B-cell-based vaccine is a novel approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Lee Chang, Catalina — Northwestern University at Chicago
- Study coordinator: Lee Chang, Catalina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.